News

Health Canada has approved Novartis Pharmaceuticals Canada’s ranibizumab (Lucentis) for the treatment of visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV).

Rayner Intraocular Lenses Ltd. have launched a new injector, RaySert Plus, in the United States market after receiving 510(k) clearance from the FDA.

The European Forum Against Blindness (EFAB) has revealed the results of an 11-country study-an extension to the data reported last year covering six countries-which reports on the economic impact of blindness and four leading eyesight conditions, and concluded that blindness and vision loss lead to a reduced quality of life and increased economic burden to society.

The judges have submitted their ballots! The readers have voted! Ophthalmology Times is pleased to announce the winner of the 2014 Resident Writers Award Program, sponsored by Allergan.

Bausch + Lomb has unveiled a new handpiece specifically designed for femtocataract surgery.

Ganglion cellular dysfunction may reverse itself as the result of a substantial decrease in IOP after trabeculectomy in patients with glaucoma, according to John Mark S. de Leon, MD.

Heidelberg Engineering has introduced a new widefield optical coherence tomography (OCT) imaging modality for its Spectralis OCT family of products.

Avedro has resubmitted its New Drug Application (NDA) for riboflavin ophthalmic solution/KXL System to the FDA.

Welcome to the latest installment of “Sight Lines,” a feature in which J.C. Noreika, MD, MBA, an ophthalmologist in Medina, OH, discusses trends in ophthalmology, medicine, and health care with key leaders in their fields. In this issue, Dr. Noreika talks with U.S. Sen. Sherrod Brown (D-OH).

Analyses of visual field data collected at centers across England showed the average level of severity of vision loss at the time of glaucoma detection decreased-improved-over time. Still, the rate of improvement between 1998 and 2012 was only 0.1 dB per year.

Although infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are a prominent concern for cataract surgeons, leading ophthalmologists discuss the pros and cons of performing universal MRSA screening to guide targeted prophylaxis.

Like you, I chose to attend medical school with the goal of helping patients who were ill and needed curing, comforting, or both. So perhaps the financial rewards of a career in medicine have made you feel slightly embarrassed and concerned that people might be resentful or jealous. Well, here’s good news: research suggests we physicians aren't so financially successful after all.

Social media is a highly effective tool for promoting practices’ campaigns, but knowing several key strategies will increase success from advertising.

The combination of camera and recorder products is designed to capture and record ophthalmic procedures for an enhanced surgical workflow.

rarely recognized. Ronald L. Fellman, MD, describes its diagnostic features and management considerations.

The effect of astigmatism varies with different factors and can affect patient satisfaction with multifocal or monofocal IOLs.

Refractive surgery screening devices do not provide results that are interchangeable.

A scleral spacing procedure for the treatment of presbyopia restored near vision in presbyopic emmetropic patients without adverse effects.

Multifocal bi-aspheric ablation profile, micromonovision approach delivers good outcomes

A hydrogel sealant demonstrated significant superiority to suturing for sealing incisions that were leaking when tested immediately after small-incision phacoemulsification and toric IOL implantation.

Boris Malyugin, MD, PhD, explains how he uses a step-wise approach to manage small pupils, starting with an intracameral injection of phenylephrine or epinephrine and eventually working up to pupil expanders.

If explantation of a miniature stainless steel glaucoma shunt becomes indicated, an ab interno technique offers several advantages compared with the traditional external approach.

Dexamethasone intravitreal implant 0.7 and 0.35 mg provided statistically and clinically significant improvement in best-corrected visual acuity and reduction in central subfield retinal thickness with an average of 4 to 5 injections over 3 years.

Technologies will provide better understanding of IOP and patient adherence to topical medications and allow timely adjustments in therapy while reducing the number of office visits.

The 2014 meeting of the American Academy of Ophthalmology will convene in Chicago from Oct. 17 to 21. Visit www.aao.org for the latest updates or to register.

Use of metformin, a drug therapy for the treatment of diabetes, was found to be associated with reduced risk of adult-onset, open-angle glaucoma in a recent study.

The FDA has approved Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.

Novaliq GmbH has reported positive phase I results with its clear cyclosporin solution eye drop formulation (CyclASol) in clinical development for patients with dry eye syndrome.

The FDA has approved Allergan’s dexamethasone intravitreal implant 0.7 mg (Ozurdex), a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME).

Bausch + Lomb’s next-generation sub-micron gel formulation of loteprednol etabonate has been found to be statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day 8-the primary endpoints in the first phase III, multicenter, double-masked, vehicle-controlled, parallel-group study.